Select Page

Press Releases

Sign up to get full access to all our latest Press Releases

Rapid Dose Announces Payment in Shares for Interest on Secured Debt

October 1, 2024


BURLINGTON, Ontario – October 1, 2024 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE) announced today that as contemplated in the secured convertible notes (the “Notes”) previously issued on its private placement financing (the “Financing”), the Company intends to issue common shares...

Rapid Dose Provides Update on Common Share Private Placement

September 16, 2024


BURLINGTON, Ontario – September 14, 2024 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE) today announced that further to its press release dated August 7, 2024, regarding a proposed equity private placement financing (the “Financing”), the Company has received an extension from...

Rapid Dose Announces Appointment of Director and Nomination of Additional Director at Upcoming Annual Meeting

August 26, 2024


BURLINGTON, Ontario – August 6, 2024 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE) announced today that it has appointed Jason Lewis as a director of the Company, effective immediately.  Mr. Lewis is Senior Vice President, Business Development, of RDT and was...

Rapid Dose Announces Closing of First Tranche of Common Share Private Placement

July 22, 2024


BURLINGTON, Ontario – July 18, 2024 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE) is pleased to announce that it has closed a first tranche of its previously announced equity private placement financing (the “Financing”) for aggregate gross proceeds of $309,000. The...

Payment in Shares for Interest on Secured Debt

July 2, 2024


BURLINGTON, Ontario – July 2, 2024 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE) announced today that as contemplated in the secured convertible notes (the “Notes”) previously issued on its private placement financing (the “Financing”), the Company intends to issue common shares...

Rapid Dose Therapeutics Reports Fiscal Year 2024 Financial Results

July 2, 2024


Burlington, Ontario – June 28, 2024 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE), is pleased to announce the filing of its financial results for the year ended February 29, 2024. Mark Upsdell, Chairman and Chief Executive Officer, stated, “Over the past...

Rapid Dose Therapeutics Vaccine Delivery Study Receives Mitacs Accelerate Grant

June 25, 2024


Burlington, Ontario – June 25, 2024 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) trading on the Canadian Securities Exchange (“CSE”) under the symbol DOSE is pleased to announce the recent award of a Mitacs Accelerate grant, with a value of $30,000 in May...

Rapid Dose Provides Update on Common Share Private Placement

June 19, 2024


BURLINGTON, Ontario – June 17, 2024 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE) today announced that further to its press release dated May 8, 2024, regarding a proposed equity private placement financing (the “Financing”), the Company has received an extension from...

Rapid Dose Therapeutics Commits to NFL-Funded Clinical Trial Application

May 29, 2024


BURLINGTON, Ontario – May 29, 2024 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE) announces its collaboration in the National Football League (NFL) – funded clinical trial program entitled “Naturally Produced Cannabinoids for Pain Management and Neuroprotection from Concussion and Participation in...

Rapid Dose Therapeutics and McMaster University’s Incorporation of Loratadine-Cyclodextrin Complexes in Oral Thin Films for Rapid Drug Delivery

May 22, 2024


Burlington, Ontario – May 22, 2024 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) trading on the Canadian Securities Exchange (“CSE”) under the symbol DOSE in partnership with McMaster University (“McMaster”) is pleased to announce the publication of the results of their collaborative research...

1 2 3 4 5 6 7 8 9 10 11 15